JPRN-UMIN000015348已完成2 期
A Multi-Center Phase II Study in Children with Newly Diagnosed Acute Promyelocytic Leukemia (APL) - JPLSG AML-P13
Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG)0 个研究点目标入组 32 人开始时间: 2014年10月6日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 18years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •17q12/RARA not detected genetically and cytogenetically APL with t(11;17)(q23;q12)/PLZF-RARA CNS hemorrhage which is likely to interfere protocol therapy Secondary APL due to previous chemotherapy or radiation therapy Unmanageable infectious disease including tuberculosis Any inappropriate status judged by physician
研究者
相似试验
已完成
2 期
A phase II, multicenter, study for newly diagnosed glioblastomas using boron neutron capture therapy, additional X-ray treatment and chemotherapyewly-diagnosed glioblastomaJPRN-UMIN000002385Dept. of Neurosurgery, Osaka Medical College45
招募中
2 期
A phase II trial for T-cell AT-cell acute lymphoblastic leukemiaPrecursor T-Cell Lymphoblastic Leukemia-LymphomaJPRN-jRCTs041210054Sato Atsushi259
进行中（未招募）
不适用
A Study of RO5185426 in Patients with Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 MutatioMetastatic or unresectable papillary thyroid cancer positive for BRAF V600 mutation and resistant to radioactive iodine therapyMedDRA version: 14.1Level: LLTClassification code 10033701Term: Papillary thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-024133-23-ITF. Hoffman-La Roche Ltd.40
进行中（未招募）
不适用
A Study of RO5185426 in Patients With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 MutatioMetastatic or unresectable papillary thyroid cancer positive for BRAFV600 mutation and resistant to radioactive iodine therapyMedDRA version: 15.1Level: LLTClassification code 10033701Term: Papillary thyroid cancerSystem Organ Class: 100000004864EUCTR2010-024133-23-NLF. Hoffman-La Roche Ltd.40
已完成
2 期
An Open-Label, Multi-Center Phase II Study of the BRAF Inhibitor Vemurafenib in Patients with Metastatic or Unresectable Papillary Thyroid Cancer (PTC) positive for the BRAF V600 Mutation and Resistant to Radioactive Iodine.Metastatic or unresectable papillary thyroid cancer10040900NL-OMON39294Hoffmann-La Roche8